Reviewing Marker Therapeutics (NASDAQ:MRKR) and Longeveron (NASDAQ:LGVN)

Longeveron (NASDAQ:LGVN) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Volatility and Risk

Longeveron has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Valuation and Earnings

This table compares Longeveron and Marker Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20 million	6.44	-$22.70 million	($9.90)	-0.24
Marker Therapeutics	$3.55 million	4.86	-$12.16 million	($0.41)	-2.52

Marker Therapeutics has higher revenue and earnings than Longeveron. Marker Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Longeveron and Marker Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1	1	1	0	2.00
Marker Therapeutics	1	1	2	0	2.25

Longeveron presently has a consensus price target of $80.00, suggesting a potential upside of 3,200.33%. Marker Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 866.18%. Given Longeveron’s higher probable upside, equities analysts plainly believe Longeveron is more favorable than Marker Therapeutics.

Insider and Institutional Ownership

10.0% of Longeveron shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 7.4% of Longeveron shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Longeveron and Marker Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
Marker Therapeutics	N/A	-56.96%	-47.82%

Summary

Marker Therapeutics beats Longeveron on 10 of the 14 factors compared between the two stocks.

About Longeveron

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

About Marker Therapeutics

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.